Needed Change in Neuropathy Testing

Research found that despite changes in guidelines for peripheral neuropathy testing, actual practices had not changed.

Author | Shoshanna Fischhoff

Millions of Americans are affected by peripheral neuropathy, a debilitating condition that causes weakness, numbness, and pain in the hands and feet.  When peripheral neuropathy is suspected, magnetic resonance imaging (MRIs) and electrodiagnostic testing (EMG) are frequently ordered and drive most diagnostic costs.  However, they rarely change the diagnosis or management of the condition.

Instead, American Academy of Neurology (AAN) guidelines recommend using certain blood tests for better diagnosis and insight into the disease. Also, the American Diabetes Association recommends against routine EMG testing and Choosing Wisely recommends against MRIs in patients with peripheral neuropathy. 

Brian Callaghan, M.D., Ph.D., the Eva L. Feldman, MD, PhD, Professor of Neurology, led a research group that looked into whether diagnostic practices had, in fact, changed since these testing guidelines and recommendations were made.  The results published in JAMA Neurology found that the ANA guidelines were not heeded, with overuse of MRIs and EMGs and underuse of certain blood tests, which Dr. Callaghan said was a problem.

“Current practice leads to too many EMG and MRI studies that are costly and do not improve the lives of patients with peripheral neuropathy,” explains Dr. Callaghan. “While at the same time, not enough simple blood tests are ordered to determine the cause of this condition. Recommendations and time are not enough to improve our practice. Instead, interventions are needed to encourage optimal care.”

Other authors: Evan L. Reynolds, Ph.D., of Michigan State University, Lavanya Muthukumar, M.S., and Melissa Elafros, M.D., Ph.D, also from University of Michigan, Leslie E. Skolarus, M.D., M.S., from Northwestern University, and James F. Burke, M.D., and Kevin A. Kerber, M.D., from Ohio State University.

Paper cited: Callaghan BC, Reynolds EL, Muthukumar L, Elafros MA, Skolarus LE, Burke JF, Kerber KA. Diagnostic Testing for Patients With Peripheral Neuropathy. JAMA Neurol. 2025 Mar 3:e250001. doi: 10.1001/jamaneurol.2025.0001. Epub ahead of print. PMID: 40029634; PMCID: PMC11877403.
In This Story
Brian C. Callaghan, MD, MS Brian C Callaghan, MD, MS

Professor

Melissa Elafros, MD, PhD Melissa Elafros, MD, PhD

Assistant Professor

Featured News & Stories Mark Hall
Department News
Inside APS: A Patient's Personal Health Journey
In 1994, Mark Hall was diagnosed with antiphospholipid syndrome (APS).
Cancer Aware
Focal therapy for prostate cancer
When treating for localized prostate cancer, surgery and radiation are usually what people hear about. However, there are other treatments that could be options under a heading of focal therapy. Dr. Andrew Wood, a urologic oncologist with U-M Health Rogel Cancer Center’s Weiser Center for Prostate Cancer talks about these options and which patients could benefit from them.
 What I'm Reading in APS Research
Department News
What I'm Reading in APS Research: June 2025
What I’m Reading in APS Research, written by Dr. Ajay Tambralli, was created to provide information about some of the latest APS research and to help everyone better understand the ins and outs of new discoveries. In this month’s edition, Dr. Tambralli explores the amazing properties of camelid antibodies and their potential applications in future therapies.
 ultrasound on skin
Health Lab
Simple muscle ultrasound may detect early prediabetes
A simple ultrasound of a patient’s thigh or shoulder muscle may detect insulin resistance before it progresses to type 2 diabetes or even prediabetes. In a study, Michigan Medicine researchers performed muscle ultrasounds on 25 patients who were also evaluated for insulin resistance.
 headshot of Zoe Yeoh
Department News
Congratulations to Zoe Yeoh, PhD
Biological Chemistry PhD student Zoe Yeoh of the Janet Smith and Melanie Ohi labs defends her doctoral dissertation.
 algae green spread all over lake by forest edge from high view
Health Lab
Living near harmful algal blooms reduces life expectancy with ALS
Living close to cyanobacterial harmful algal blooms — which are present nationwide but are more common in coastal and Great Lake states — heightens the rate of dying from amyotrophic lateral sclerosis, or ALS, a study suggests.